Independent Equity Research
The Midrey

Long-form research on US mid, small, and micro caps.

Written for investors who want to understand a sector without having spent fifteen years inside it. Every figure in every note ties back to a filing the company sent to the SEC. No paid databases, no expert calls, no positions in any name we cover. The first note ships later this year.

What we cover, and why

Mid, small, and micro-cap US-listed companies sit in a coverage gap. The big banks mostly ignore them. The boutique sell-side firms write for other specialists, in language you need a decade in the sector to follow. If you want to understand these names and you're willing to put in the work, you're stuck with marketing decks and message boards. That's the gap we write into.

01

Mid, small, and micro caps

We focus on US-listed names where what's already published is thin, stale, or written for analysts who already live in the sector. The point is to find businesses worth real work, not the ones already crowded with coverage.

02

The sector before the argument

Every note opens with how the business actually runs: unit economics, regulatory regime, channel, customer. The thesis comes after that, in plain language. You shouldn't need a finance background to follow the argument.

03

Sources from EDGAR, full stop

Every figure ties back to something the company filed with the SEC: 10-Ks, 10-Qs, 8-Ks, proxies, registration statements, and the exhibits attached. No paid databases, no expert networks, no off-record briefings. The source ledger lists every EDGAR accession number, so anyone can pull the original document themselves, free.

How a note is made

Six phases   ·   The full process →

Every claim is built on visible, inspectable evidence within the note itself.

Notes are built in six phases (intake, diligence, modelling, review, publish, maintain). Every phase writes to the same source ledger the reader sees. That ledger is the bridge between what the analyst is claiming and what the company actually filed.

When the model disagrees with the market, we describe the asymmetry and stop short of telling you to trade on it. When we're uncertain, we show the band and say why. When we've been wrong, the changelog is dated and signed.

01
Intake
The companies we cover are not selected based on a written coverage mandate, this helps us to be independent and unbiased, thus preventing conflict.
02
Diligence
Research is built primarily from company filings, including 10-Ks, 10-Qs, 8-Ks, proxy filings, and registration statements, all linked back to original SEC documents.
03
Modelling
All assumptions, scenarios, and sensitivity analyses are shown transparently. No hidden adjustments or black-box models.
04
Review
Every note goes through editorial and peer review, including a dedicated challenge process for the core thesis.
05
Publish
Published notes are timestamped, and versioned from our end before publishing.
06
Maintain
Coverage is refreshed quarterly, with major developments and thesis changes tracked in a public changelog.
Editorial policy

No ratings. No positions. No conclusion that replaces yours.

Buy, sell, and hold are decisions that turn on a horizon, a mandate, and a risk tolerance the analyst doesn't share. We believe that equity research is more than mere stock picking.

No positions in covered names

The firm holds no positions in any name under coverage or under active consideration. The holdings policy is dated, filed, and audited. We have no vested interest in any of the companies.

Subscribers only

Research revenue comes from subscribers. We don't accept issuer compensation, investment-banking mandates, soft-dollar arrangements, or paid placement of any kind.

Public changelog

Every material revision is logged with date, reason, and signature on the company page of record. Revisions are not deleted. The record of what we got wrong stays part of the record.

Be told when the first note ships.

One email when we publish. No marketing in between, no drip sequence, no second list we sell to anyone.